Trends and Innovations in Companion Diagnostics

Trends and Innovations in Companion Diagnostics

Code: FW-21072016-18 | Published: Apr-2016 | Pages: 0 | FirstWord
Price :

* Required Fields



Are companion diagnostics becoming a “must have” for market access?

Companion Diagnostics (CDx) are playing an increasingly vital role in market access by supporting product value claims and improving patient outcomes. What are the upsides for developers, pharma, payers and physicians and how can the challenges around new technology adoption, reimbursement and clinician uptake be overcome?

To really understand the issues and trends that are shaping the CDx market, senior managers in diagnostic development companies and the pharma industry should turn to this report.

“Pharma companies around the world are scouring tumour cells to find something different. It’s logical that detecting those differences would in fact then be down to a companion diagnostic.” Rob Steitz, Insight Genetics Inc.

Answering key questions:

Pharma’s benefit: Are CDx becoming essential for regulatory approval and clinical diagnosis?
New therapy areas: Beyond oncology, what therapy areas are being targeted by CDx?
All in the timing: At what stage should CDx be included in a drug’s development?
New technologies: How revolutionary will next generation sequencing, liquid tumour testing, biopsies and bioinformatics be in driving future uptake of CDx?
Engaging Physicians: Many physicians do not use approved CDx, or choose alternatives. Should the use of approved CDx be mandatory and enforced?
Where’s the money? Reimbursement models do not reflect the wider value of advanced CDx – what are the options for change and how is this influencing developers thinking and investment?
Point of Care: What are the future prospects for the development of PoC CDx?

With this report you will be able to:

Identify the new CDx approaches and evaluate their benefits.
Understand how and where they will impact the market and review the challenges they must overcome.
Assess the activities, policies and partnerships of CDx-progressive pharma companies.
Understand how financial and reimbursement models need to change to reflect the real value of CDx.
Learn how advanced CDx can radically improve clinical trial research and outcomes.
Formulate strategies that encourage physicians to use approved CDx.
Identify the therapy areas and conditions where next generation CDx will make an impact.
Grasp the growing importance of research consortia in the identification of biomarkers.

Key Topics Explored:

Pharma is sometimes compelled to identify a CDx as part of securing regulatory approval, but physicians are not obligated to use it. Is it time to make their use mandatory?
Reimbursement models do not allow for premium pricing of advanced CDx. Taking potential cost savings and improved patient outcomes into account, isn’t it time that a fair price was paid?
Some pharma companies may see CDx as unnecessary revenue capping, while others take a more progressive view. Will the benefits of CDx mean they become key in supporting value claims and securing market access?
Pharmaceutical companies, diagnostic companies, patients, physicians, payers, testing laboratories and regulators are all stakeholders. They should be engaged as early as possible.
Payers have most to benefit by using CDx to ensure that expensive drugs are prescribed optimally, so why are some payers concerned?

Expert Contributors

Frank Apostel, VP Companion Diagnostics, R-Biopharm AG, Germany
Joachim Reischl, VP Head of Policy, Portfolio and Externalisation, Personalised Healthcare, AstraZeneca, EU
Richard Watts, Vice President, Companion Diagnostic Partnerships, Global Business Development, QIAGEN, USA
Rob Seitz, Chief Technology Officer, Insight Genetics Inc., USA
William Pignato, Regulatory Affairs Consultant, Companion Diagnostic, USA
Director, CDx Development, Japanese Pharma Company
Director, Corporate Development, European Diagnostic Company
Companion Diagnostic Expert, Global Diagnostic Company
Companion Diagnostic Expert, Specialist Diagnostic Company

All respondents met FirstWord’s stringent screening criteria, and were compensated for participating. To encourage frank and forthright responses, their names have been withheld.

Table of Contents

1 Executive Summary
2 Research Objectives
2.1 Research Methodology
2.2 Definitions
3 Setting the scene
4 Clinical and economic benefits of developing a companion diagnostic
5 Recent innovations in precision medicine and companion diagnostics
6 Recent technological innovations in companion diagnostics
7 Drivers and inhibitors for the uptake of CDx
8 Factors influencing successful/unsuccessful partnerships
9 Optimal and sub-optimal practice for developing companion diagnostics
10 Regulatory impact on the development and uptake of CDx
11 Managing stakeholder expectations on CDx programmes
12 What needs to be done to encourage future innovation in CDx development?
13 Future opportunities in CDx and precision medicines
14 Appendix

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare

Our Clients